<div>Dr. Margarita Fedorova discusses the DRAIN trial and the efficacy of acetazolamide in idiopathic normal pressure hydrocephalus. </div> <p>Show citation: </p> <p>Virhammar J, Fasth O, Ekblom M, et al. Safety, tolerability, and efficacy of acetazolamide in idiopathic normal pressure hydrocephalus (DRAIN) in Sweden: a randomised, double-blind, placebo-controlled, phase 2 trial. <em>Lancet Neurol</em>. 2026;25(6):550-559. doi:<a href= "https://linkinghub.elsevier.com/retrieve/pii/S1474442226001262" target="_blank" rel= "noopener">10.1016/S1474-4422(26)00126-2</a> <br /> <br /></p>

When Drug Marketing Masquerades as Clinical Trials

The Neurology Minute podcast delivers a brief daily summary of what you need to know in the field of neurology, the latest science focused on the brain, and timely topics explored by leading neurologists and neuroscientists. From the American Academy of Neurology and hosted by Stacey Clardy, MD, Ph.D., FAAN, with contributions by experts from the Neurology journals, Neurology Today, Continuum, and more.